BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 05/27/22

SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and...

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) said it has set up a new corporate and research and development facility at The Boardwalk at Science Center Drive in San Diego, California to support translational R&D for cell therapies and genetic medicines. “The opening of our state-of-th...

SAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with canc...

Shares of Brooklyn ImmunoTherapeutics (NASDAQ:BTX) have fallen 11.9% on Monday in afternoon trading, after the clinical-stage biopharmaceutical company reported on April 15 its Q4 and FY 2021 results. BTX stock has lost ~61% YTD as of last close, snapping a six-session losing streak only last...

Brooklyn Immunotherapeutics press release (NASDAQ:BTX): Q4 GAAP EPS of -$0.16. As of December 31, 2021, Brooklyn had ~$17.0M in cash, compared to $1.6M as of December 31, 2020. For further details see: Brooklyn Immunotherapeutics GAAP EPS of -$0.16

SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, a...

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and mon...

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) has announced a $12M private placement agreement with a healthcare investor. Under the agreement, Brooklyn will issue 6,857,142 units priced at $1.75 each. Each unit consists of one common stock and one warrant to purchase additional share at exercise ...

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and mon...

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders...